Core Viewpoint - The article discusses the upcoming bilateral talks between the U.S. and Mexico as part of the USMCA joint review process, focusing on trade issues such as tariffs, market access, and supply chain security [3][4]. Group 1: USMCA Joint Review Process - The U.S. and Mexico will hold bilateral talks to discuss measures to ensure the USMCA benefits all parties, including reducing reliance on external imports and strengthening origin rules [3][4]. - The USMCA includes a "sunset clause" requiring a joint review six years after its implementation, with a decision on extending the agreement due by July 1, 2026 [5]. - The U.S. Trade Representative's office has indicated that the outcome of the joint review will depend on resolving issues related to origin rules for non-automotive industrial products and economic security collaboration [5]. Group 2: Tariffs and Market Access - Mexico aims to avoid significant modifications to the USMCA and seeks to optimize the dispute resolution mechanism to limit unilateral tariffs imposed by the U.S. [4]. - The U.S. has previously imposed a 25% tariff on certain Mexican imports, which was recently ruled invalid by the U.S. Supreme Court, but Mexico may leverage the joint review to seek exemptions from these tariffs [6][9]. - The automotive sector in Mexico has been affected by tariffs, with the industry experiencing a decline in production and exports, losing nearly $2.7 billion in 2025 [8]. Group 3: Negotiation Leverage - The high dependency of U.S. companies on Mexican supply chains provides Mexico with leverage in negotiations, as the integration of North American manufacturing spans various industries [8]. - Advanced technology products accounted for 27% of U.S. imports from Mexico in 2025, highlighting the importance of this trade relationship [8]. - Mexican officials emphasize the need to eliminate tariffs and establish clear trade rules to mitigate uncertainty and its impact on investment [9].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Suzhou Basecare Medical Corporation Limited 蘇 州 貝 康 醫 療 股 份 有 限 公 司 本公告由蘇州貝康醫療股份有限公司（「本公司」，連同其子公司統稱「本集團」） 自願刊發，以告知本公司股東及潛在投資者有關本集團業務的最新發展。 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2170） 自願公告 PGT-A試劑盒獲國家藥監局頒發醫療器械註冊證 本公司董事會（「董事會」）欣然宣佈，本公司基於國產高通量基因測序平台的 PGT-A試劑盒，胚胎植入前染色體非整倍體檢測試劑盒（聯合探針錨定聚合測 序法），於2026年3月13日成功獲批國家三類醫療器械註冊證（註冊證號：國械 註準20263400529），成為全國首個基於純國產自主平台測序儀的PGT-A試劑盒。 此試劑盒適用於35歲及以上試管嬰兒患者、染色體異常夫婦、三 ...

Investment Rating - The report assigns an investment rating of "Outperform the Market" for the pharmaceutical sector, indicating a relative performance better than the benchmark index [2][4]. Core Insights - The pharmaceutical sector is experiencing a mixed performance, with the SW Pharmaceutical Biotechnology Index declining by 0.22%, ranking 13th out of 31 sectors, underperforming the CSI 300 Index which increased by 0.19% [2]. - The approval of the world's first invasive brain-computer interface medical device in China marks a significant milestone, indicating the commercialization of brain-computer interface technology and addressing a substantial medical need for spinal cord injury patients [2]. - Eli Lilly plans to invest $3 billion over the next decade to expand its supply chain in China, focusing on local production capabilities for oral solid formulations, which reflects the growing importance of Chinese pharmaceutical companies in global innovation [2]. Summary by Sections Industry Performance - The pharmaceutical sector's performance is influenced by geopolitical events, with energy sectors leading the market while medical devices and CXO sectors lagged [2]. - Notable segments such as medical consumables and raw materials showed positive growth, while medical devices and CXO faced declines [2]. Key Developments - The brain-computer interface device approved for clinical use is designed for patients with specific spinal cord injuries, showcasing significant improvements in hand function and quality of life [2]. - The National Healthcare Security Administration has established pricing projects for brain-computer interface technology, facilitating its clinical application [2]. Investment Opportunities - The report highlights investment opportunities in areas such as ADC, dual antibodies, small nucleic acids, and weight-loss drugs, with a focus on companies like Innovent Biologics, 3SBio, and others [2]. - The report emphasizes the potential for long-term investment in China's pharmaceutical innovation, particularly in the context of increasing international collaboration and investment from multinational corporations [2].

Group 1: Pharmaceutical Industry - The pharmaceutical industry is undergoing a significant transformation due to deep medical reforms, leading to a shift in cost structures and business models [2][7] - A sample of 16 major U.S. pharmaceutical companies shows an annual revenue growth rate of 4.2% over the past decade, with a projected growth rate of 5.2% for 2025 [2] - The overall price-to-sales (PS) ratio for these companies has increased from around 2.5x during the financial crisis to over 5x in recent years, indicating a bullish market sentiment [2][3] - The average gross margin for these companies is approximately 73%-74%, with a projected increase to 75%-76% in 2025, reflecting strong long-term profitability [3] - There has been a notable shift in the expense structure, with R&D expenses increasing from 16.4% to 21.8% by 2025, while sales and administrative expenses have decreased significantly [4][6] Group 2: Medical Device Industry - The medical device industry has not experienced the same structural changes as the pharmaceutical sector, with sales and R&D expense ratios remaining stable over the past two decades [6][10] - A virtual company combining 11 major U.S. medical device firms has seen revenue growth of 206% from 2006 to 2025, indicating a more stable growth trajectory compared to pharmaceuticals [12] - New leaders in the medical device sector are emerging from innovative product categories, showing higher growth rates and returns compared to established companies [13][17] - The lack of significant regulatory reforms in the medical device sector contrasts with the pharmaceutical industry, which has seen substantial policy changes that enhance innovation and R&D returns [9][10] Group 3: Distribution and Circulation - The U.S. pharmaceutical distribution market is highly concentrated, with three major companies experiencing accelerated revenue growth since 2021, benefiting from high inflation and strategic acquisitions [23][25] - In contrast, Chinese pharmaceutical distributors have faced a significant slowdown in revenue growth, with some companies experiencing negative growth rates [25][27] - The valuation of Chinese pharmaceutical distributors has decreased significantly compared to their U.S. counterparts, indicating a potential investment opportunity as the market stabilizes [25][29] Group 4: Other Segments - The PBM (Pharmacy Benefit Management) sector in the U.S. is facing challenges due to potential government interventions in drug pricing, which may impact profitability [31] - Laboratory equipment and biotech services are expected to grow due to increased R&D spending in the pharmaceutical industry, presenting opportunities for domestic companies [32] - The hospital sector in the U.S. has begun to recover from prolonged pressure, with improved profitability expected as competition stabilizes [33]

Core Viewpoint - Shenzhen Baitwei Medical Technology Co., Ltd. has achieved breakthroughs in domestic peripheral vascular intervention devices and completed nearly 100 million RMB in Series B financing to accelerate innovation in the peripheral vascular intervention and heart failure fields [2][4]. Group 1: Product Development and Innovation - Baitwei Medical has established a comprehensive product matrix in the peripheral vascular intervention field, covering "reduction + thrombectomy + access," with several technologies at a leading domestic level [4]. - The company's independently developed peripheral venous thrombectomy system is the only domestic product approved for the "Innovative Medical Device Special Review Green Channel" [4]. - Baitwei Medical is also developing a pulmonary artery thrombectomy system, which is the only self-expanding stent thrombectomy system in China, directly competing with foreign second-generation products [5]. Group 2: Focus on Heart Failure - The company is focusing on heart failure, a critical area in cardiovascular diseases, and aims to develop a comprehensive device solution, particularly targeting the atrial shunt system, to fill a gap in domestic treatment options [10]. - Baitwei Medical is one of the few companies globally to enter the clinical stage for atrial shunt systems, with plans to create the first non-implantable atrial shunt system in the world [10]. Group 3: Strategic Financing and Future Plans - The recent financing round will be used for new product development, construction of production bases, and market expansion, laying a solid foundation for the company's next five years of development [11]. - The company has established a domestic sales headquarters in Beijing, which will support its operational growth [11]. - Investors express confidence in Baitwei Medical's innovative capabilities and its systematic layout in high-potential areas, emphasizing the company's strong research and development transformation capabilities [11].

Core Viewpoint - The successful IPO of Guangzhou Kelairedi Medical Equipment Co., Ltd. on the Beijing Stock Exchange marks a significant turnaround for the company after its previous failure on the ChiNext board, reflecting a new trend in the medical device industry where companies adjust their business structures and capital paths to reattempt listing [4][15]. Industry Overview - Kelairedi operates in the field of tumor radiation therapy auxiliary equipment, which is one of the three main treatment methods for tumors alongside surgery and chemotherapy. The increasing incidence of tumors and advancements in precision medicine are driving the growing application of radiation therapy [5][8]. - The positioning and fixation devices used in radiation therapy are critical for ensuring treatment accuracy, as patients require consistent positioning over multiple sessions [5][8]. Company Profile - Founded in 2001 and headquartered in Guangzhou, Kelairedi focuses on the research, production, and sales of positioning devices for radiation therapy and rehabilitation aids. The company ranks third globally in the positioning product market with a 7.0% market share and leads the domestic market with a 42.5% share [9][11]. - Kelairedi has accumulated multiple patents in low-temperature thermoplastic materials, positioning films, and shaping pads, and its products are sold both domestically and through overseas distributors [11]. Financial Performance - Kelairedi's revenue has remained stable, with approximately CNY 238 million (around USD 33 million) in 2023, showing a slight increase from CNY 233 million in 2022. However, the company's profit margins are relatively small, with a net profit of approximately CNY 3.1 million in 2023, down from CNY 6.77 million in 2022 [13][14]. - The company's total assets were about CNY 329 million, with net assets around CNY 163 million by the end of 2023, indicating it operates as a typical mid-sized medical device company with stable revenue but limited profit capacity [14]. IPO Pathway Analysis - Kelairedi's transition from the ChiNext board to the Beijing Stock Exchange highlights the suitability of the latter for mid-sized manufacturing enterprises, particularly those with revenues between CNY 200 million and CNY 500 million and smaller profit margins [17]. - The recognition of niche medical device companies has increased as the domestic medical device supply chain matures, allowing smaller firms to gain acceptance in the capital market [18]. - Kelairedi's current stable growth phase aligns well with the Beijing Stock Exchange's market positioning, suggesting that more mid-sized medical device companies may consider this exchange for their IPOs in the future [19].

Investment Rating - The investment rating for the pharmaceutical industry is "Overweight," indicating a positive outlook for the sector compared to the overall market performance [28]. Core Insights - The pharmaceutical sector's performance this week saw a decline of 0.2%, while the Shanghai Composite Index fell by 0.7% and the Wind All A Index (excluding finance, oil, and petrochemicals) decreased by 0.5%. The pharmaceutical index ranked 13th among 31 sub-industries [2][3]. - The overall valuation of the pharmaceutical sector is at 30.3 times earnings, ranking 12th among 31 primary industries [6][12]. - Recent developments include the approval of the world's first invasive brain-computer interface in China, aimed at assisting patients with spinal cord injuries [10][13]. - New drug research remains active, with significant clinical trial results reported for various drugs, including the CSF-1R inhibitor and treatments for epilepsy and sepsis [14][15][16]. Market Performance - The pharmaceutical index's performance this week was -0.2%, with various sub-sectors showing mixed results. Notable increases were seen in raw materials (+1.3%) and vaccines (+1.3%), while medical devices experienced a decline of -2.0% [2][6][8]. - The pharmaceutical sector's performance is ranked 13th among 31 sub-industries, indicating a relatively stable position within the broader market context [3][6]. Recent Key Events - The Jiangsu Province has launched an action plan for the innovation and development of the brain-computer interface industry, aiming for significant advancements by 2027 [10][11]. - The acquisition of the Vietnamese pharmaceutical company IMP by Lijun Pharmaceutical has been approved, marking a strategic expansion for the company [17]. - Collaboration between Kanglong Chemical and Eli Lilly for the production of Orforglipron has been established, with an expected investment of $200 million from Eli Lilly [19]. Company Developments - Recent clinical trial results for the CSF-1R inhibitor, published in The Lancet, showed a significant improvement in treatment outcomes compared to placebo [14]. - Xenon Pharmaceuticals reported positive results from a Phase III trial for Azetukalner, indicating a substantial reduction in seizure frequency [15]. - Iwubio's IND application for a mesenchymal stem cell injection for sepsis has been accepted, highlighting ongoing innovation in treatment options [16]. Investment Recommendations - Investors are advised to monitor companies involved in raw material production due to recent price increases, including New Harmony, Zhejiang Pharmaceutical, and Tianxin Pharmaceutical [2]. - Continued focus on innovative drug development is recommended, with specific attention to companies like Heng Rui Pharmaceutical and BeiGene [2]. - The brain-computer interface sector is highlighted for potential investment opportunities, particularly in companies such as Aipeng Medical and Xiangyu Medical [2].

Market Updates - JD Health (06618) rose over 4.5% following a strategic partnership announcement with leading medical device brand Yuyue Medical [1] - Kangfang Biopharma (09926) increased by over 5.7% after receiving NMPA clinical trial approval for its novel tri-specific antibody drug AK150 for treating advanced malignant solid tumors [1] - Yunfeng Financial (00376) saw a significant rise of 14.18%, with a previous day increase of over 10%, amid a temporary suspension announcement related to a major stock price surge [1] - Steel stocks collectively declined, with Asia Pacific Resources (01104) down 7.59% and Maanshan Iron & Steel (00323) down 7.28% [1] Earnings Warnings and Gains - Jiuyuan Group (00827) fell over 20% after issuing a profit warning, projecting a net loss of approximately RMB 709 million for the year ending December 31, 2025, an increase from a loss of RMB 505 million in 2024 [2] - Changfeng Pharmaceutical (02652) surged nearly 43% after announcing that its inhalation powder ICF001 for treating pulmonary arterial hypertension has received NMPA acceptance for clinical trial application [2] - Yicheng Industrial (01596) rose over 76% after announcing a projected net profit of approximately RMB 334 million for the year ending December 31, 2025, compared to a net loss of RMB 57.7 million in 2024 [3] - Akeso Biopharma (09939) increased by over 10.7% following a strategic cooperation agreement with Funo Pharmaceuticals to develop a new cosmetic product [3] Other Notable Movements - Soundon Technology (02495) rose over 5% after projecting a net profit of no less than RMB 120 million for the year ending December 31, 2025, compared to a net loss of RMB 481 million in 2024 [4] - Starry Chain Group (00399) saw an increase of 18.52% after announcing a memorandum of understanding with Newbridge Acquisition Limited for potential acquisition opportunities [4] US Market Highlights - Tencent Holdings (ADR) (TCEHY.US) rose 1.11% as it welcomed Apple's adjustment of App Store commission policies in China [5] - Meta (META.US) fell 3.83%, marking its largest intraday drop since March 6, due to delays in the release of its new AI model [5] - Ulta Beauty (ULTA.US) dropped 14.24% despite strong same-store sales growth, as fourth-quarter profits fell short of expectations [5] - Bitcoin rose over 5% to $73,764, while Ethereum increased over 6.5% to $2,201.41, reflecting a positive trend in the cryptocurrency sector [6]

Investment Rating - The report maintains an "Overweight" rating for the brain-computer interface (BCI) industry, indicating a positive outlook compared to the market benchmark [4][12]. Core Insights - The brain-computer interface industry is expected to experience significant development opportunities driven by technological innovations, policy support, and capital investments, leading to demand release in downstream markets such as healthcare and consumer products [2]. - The global market for brain-computer interfaces is at a critical turning point characterized by technological breakthroughs, clinical validations, and commercial implementations, suggesting a promising future for the industry [5]. Summary by Sections Industry Overview - The report highlights the approval of the world's first invasive brain-computer medical device by the National Medical Products Administration (NMPA), marking a significant milestone in clinical application [5]. - The device, developed by Boruikang, is designed to assist patients with quadriplegia due to cervical spinal cord injuries, demonstrating improved hand function and quality of life through innovative technology [5]. Clinical and Regulatory Developments - The clinical trials for the device showed a 100% success rate in achieving primary clinical endpoints, with over 7,000 days of safe implantation reported by the end of 2025 [5]. - The NMPA has prioritized resources for the review and approval of innovative products in the BCI sector, expediting the market entry process [5]. Policy and Market Support - The report notes that the Chinese government is actively encouraging the development of the BCI industry, with plans to establish a robust industrial system by 2030 [5]. - Recent policy initiatives have provided clear cost references for hospitals regarding BCI device procurement, enhancing confidence in the technology's application in medical settings [5]. Investment Recommendations - The report recommends specific companies for investment, including Lepu Medical, Kefu Medical, and Weisi Medical, while suggesting attention to other firms such as Xiangyu Medical and Aipeng Medical [5][6].

Summary of Conference Call on Disposable Glove Industry Industry Overview - The disposable glove industry is experiencing price increases driven by supply-side factors, including the exit of small manufacturers and rising energy/raw material costs, leading to an upward shift in profit margins. [1] - The industry is expected to reach a supply-demand balance by 2024, with some medium-sized manufacturers operating at low capacity and small manufacturers exiting the market, setting the stage for price increases. [2] Key Companies and Their Performance Yingke Medical - Yingke Medical is a leading global manufacturer of disposable gloves, with total production capacity expected to reach 72.1 billion pieces by the end of 2025. [3] - The company has a self-supply rate of 70%-80% for nitrile latex, which enhances its cost advantage. Profit per glove is projected to increase from 2 cents to 3-4 cents. [3] - The expected operating profit for Yingke Medical is around 15 billion yuan, with potential to exceed 20 billion yuan by 2027 due to capacity expansion and industry profit increases. [3] Zhonghong Medical and Blue Sail Medical - Both companies were operating at a loss in 2025 but turned profitable by April 2026, with profit per glove around 1 cent. [5] - Zhonghong Medical has a nitrile glove capacity of 17.1 billion pieces, while Blue Sail Medical has 25.1 billion pieces, with an additional 4 billion pieces that can be adjusted based on demand. [5] - Estimated annual profits for Zhonghong Medical are around 180 million yuan, while Blue Sail Medical's profits are expected to be close to 200 million yuan. [5] Pricing and Profit Elasticity - The price of gloves is expected to rise from $17 to $23-24 per thousand gloves, with a cost increase of approximately $2, indicating significant profit elasticity. [1][7] - The current market conditions suggest that the price increase will not significantly affect demand, as the primary applications for disposable gloves are in the medical field, which has stable demand. [10] Risks and Monitoring - The supply of low-cost raw materials is expected to last until mid-May 2026, after which the impact of high-cost raw material procurement on profits will need to be monitored. [1][8] - The market is also concerned about the potential for demand shrinkage due to price increases, but historical data suggests that demand remains stable even with significant price hikes. [10] Additional Insights - The cost advantages of companies using coal over those using natural gas are expected to widen, further enhancing profitability for companies like Yingke Medical. [2][3] - The potential for PVC gloves to replace nitrile gloves is limited due to performance differences, and no significant trends toward substitution have been observed. [10]